


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


Claim 1 (previously amended): An isolated and purified Annonaceous acetogenin compound having the structure of:

a. muricin A having the formula of:




said muricin A having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-15 and C-18 with one flanking hydroxyl in a threo conformation, two methylene groups of the mono-THF ring corresponding to a trans conformation, two hydroxyl groups at C-26 and C-27 as vicinal diol assigned as threo based, and the stereochemistry at C-34 on the γ -lactone fragment performed in (S)-configuration;

b. muricin B having the formula of:




said muricin B having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-15 and C-18 with one flanking hydroxyl in a trans/threo conformation, two methylene groups of the mono-THF ring corresponding to a trans conformation, two hydroxyl groups at C-26 and C-27 as vicinal diol assigned as threo based, and the stereochemistry at C-34 on the γ -lactone fragment performed in (S)-configuration;

c. muricin C having the formula of:




said muricin C having an α, β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-17 and C-20 with one flanking hydroxyl in a trans/threo or threo/trans conformation, two hydroxyl groups at C-24 and C-25 as vicinal diol assigned as threo based, and the stereochemistry at C-34 on the γ -lactone fragment performed in (S)-configuration;

d. muricin D having the formula of:




said muricin D having an α, β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-15 and C-18 with one flanking hydroxyl in a threo/trans conformation, two hydroxyl groups at C-22 and C-23 as vicinal diol assigned as threo based;

e. muricin E having the formula of:




said muricin E having an α, β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-12 and C-15 with one flanking hydroxyl in a threo/trans conformation, two hydroxyl groups at C-22 and C-23 as vicinal diol assigned as threo based;

f. muricin F having the formula of:



said muricin F having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-17 and C-20 with one flanking hydroxyl in a threo/trans conformation, two hydroxyl groups at C-27 and C-28 as vicinal diol assigned as threo based, and a double bond determined at C-24/C-25; or

g. muricin G having the formula of:



said muricin G having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-16 and C-19 with one flanking hydroxyl in a threo/trans/threo conformation, one hydroxyl groups formed at C-10, a double bond determined at C-23/C-24, and the stereochemistry at C-34 on the γ -lactone fragment performed in (S)-configuration.


Claim 2 (previously amended): A method for isolating Annonaceous acetogenins compounds from *Annona muricata* seeds comprising:

extracting said Annonaceous acetogenins compounds from said *Annona muricata* seeds with MeOH to obtain a MeOH extract at room[.] temperature; and
 evaporating said MeOH from said MeOH extract; and

partitioning said evaporated MeOH extract in a CHCl_3 and aqueous mixture, whereby said Annonaceous acetogenins compounds are in said CHCl_3 layer of said CHCl_3 and aqueous mixture;


wherein said Annonaceous acetogenins compounds comprise

a. muricin A having the formula of:




said muricin A having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-15 and C-18 with one flanking hydroxyl in a threo conformation, two methylene groups of the mono-THF ring corresponding to a trans conformation, two hydroxyl groups at C-26 and C-27 as vicinal diol assigned as threo based, and the stereochemistry at C-34 on the γ -lactone fragment performed in (S)-configuration;

b. muricin B having the formula of:




said muricin B having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-15 and C-18 with one flanking hydroxyl in a trans/threo conformation, two methylene groups of the mono-THF ring corresponding to a trans conformation, two hydroxyl groups at C-26 and C-27 as vicinal diol assigned as threo based, and the stereochemistry at C-34 on the γ -lactone fragment performed in (S)-configuration;

c. muricin C having the formula of:




said muricin C having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-17 and C-20 with one flanking hydroxyl in a trans/threo or threo/trans conformation, two hydroxyl groups at C-24 and C-25 as vicinal diol assigned as threo based, and the stereochemistry at C-34 on the γ -lactone fragment performed in (S)-configuration;

d. muricin D having the formula of:




said muricin D having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-15 and C-18 with one flanking hydroxyl in a threo/trans conformation, two hydroxyl groups at C-22 and C-23 as vicinal diol assigned as threo based;

e. muricin E having the formula of:




said muricin E having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-12 and C-15 with one flanking hydroxyl in a threo/trans conformation, two hydroxyl groups at C-22 and C-23 as vicinal diol assigned as threo based;

f. muricin F having the formula of:



said muricin F having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-17 and C-20 with one flanking hydroxyl in a threo/trans conformation, two hydroxyl groups at C-27 and C-28 as vicinal diol assigned as threo based, and a double bond determined at C-24/C-25; and

g. muricin G having the formula of:



said muricin G having an α , β -unsaturated γ -lactone with a hydroxyl group at C-4, a mono-THF ring placed between C-16 and C-19 with one flanking hydroxyl in a threo/trans/threo conformation, one hydroxyl groups formed at C-10, a double bond determined at C-23/C-24, and the stereochemistry at C-34 on the γ -lactone fragment performed in (S)-configuration.

Claims 3-4 (cancelled).

Claim 5 (previously amended): A pharmaceutical composition comprising said Annonaceous acetogenin compound of claim 1, and a pharmaceutically acceptable carrier.

Claims 6-9 (cancelled). :

Claim 10 (previously amended): The Annonaceous acetogenins compound according to claim 1, wherein said compound is isolated from *Annona muricata*.

Claim 11 (previously amended): The Annonaceous acetogenins compound according to claim 10, wherein said compound is isolated from seeds of *Annona muricata*.

Claims 12-18 (cancelled).

Claim 19 (previously amended): A method for separating said Annonaceous acetogenins compounds according to claim 2 [[1]], comprising:

collecting said CHCl_3 layer;

loading said CHCl_3 layer onto a ~~an~~ Si gel column and eluting said Annonaceous acetogenins compounds from said Si gel column with a gradient containing n-hexane- CHCl_3 and CHCl_3 -MeOH into 10 fractions; and

collecting fraction 7 and fraction 8 eluted from said Si gel column;

whereby muricin A, muricin B, muricin C, and muricin F are in fraction 7 of the Si gel column; and muricin D, muricin E, and muricin G are in fraction 8 of the Si gel column.

Claim 20 (cancelled):

Claim 21 (previously amended): The method according to claim 23, wherein said reversed-phased HPLC is an ODS-5 column with MeOH-water at a volume ratio of about 88:12.

Claim 22 (previously presented): The method according to claim 17, wherein said reversed-phased HPLC is an ODS-5 column with MeOH-water at a volume ratio of about 86:14.

Claim 23 (previously presented): The method according to claim 19, wherein said muricin A, said muricin B, said muricin C, and said muricin F of said fraction 7 are further separated by a reversed-phase high performance liquid chromatography.

Claim 24 (previously presented): The method according to claim 19, wherein said muricin D, said muricin E, and said muricin G of said fraction 8 are further separated by a reversed-phase high performance liquid chromatography.